The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory infection in Kenya
- PMID: 39232690
- PMCID: PMC11375914
- DOI: 10.1186/s12889-024-19875-y
The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory infection in Kenya
Abstract
Background: Respiratory syncytial virus (RSV) is one of the main causes of hospitalization for lower respiratory tract infection in children under five years of age globally. Maternal vaccines and monoclonal antibodies for RSV prevention among infants are approved for use in high income countries. However, data are limited on the economic burden of RSV disease from low- and middle-income countries (LMIC) to inform decision making on prioritization and introduction of such interventions. This study aimed to estimate household and health system costs associated with childhood RSV in Kenya.
Methods: A structured questionnaire was administered to caregivers of children aged < 5 years admitted to referral hospitals in Kilifi (coastal Kenya) and Siaya (western Kenya) with symptoms of acute lower respiratory tract infection (LRTI) during the 2019-2021 RSV seasons. These children had been enrolled in ongoing in-patient surveillance for respiratory viruses. Household expenditures on direct and indirect medical costs were collected 10 days prior to, during, and two weeks post hospitalization. Aggregated health system costs were acquired from the hospital administration and were included to calculate the cost per episode of hospitalized RSV illness.
Results: We enrolled a total of 241 and 184 participants from Kilifi and Siaya hospitals, respectively. Out of these, 79 (32.9%) in Kilifi and 21(11.4%) in Siaya, tested positive for RSV infection. The total (health system and household) mean costs per episode of severe RSV illness was USD 329 (95% confidence interval (95% CI): 251-408 ) in Kilifi and USD 527 (95% CI: 405- 649) in Siaya. Household costs were USD 67 (95% CI: 54-80) and USD 172 (95% CI: 131- 214) in Kilifi and Siaya, respectively. Mean direct medical costs to the household during hospitalization were USD 11 (95% CI: 10-12) and USD 67 (95% CI: 51-83) among Kilifi and Siaya participants, respectively. Observed costs were lower in Kilifi due to differences in healthcare administration.
Conclusions: RSV-associated disease among young children leads to a substantial economic burden to both families and the health system in Kenya. This burden may differ between Counties in Kenya and similar multi-site studies are advised to support cost-effectiveness analyses.
Keywords: Cost; Health System; Hospitalization; Households; Respiratory syncytial virus.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa.BMC Med. 2023 Mar 31;21(1):120. doi: 10.1186/s12916-023-02806-w. BMC Med. 2023. PMID: 37004062 Free PMC article.
-
Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.J Glob Health. 2017 Jun;7(1):010412. doi: 10.7189/jogh.07.010412. J Glob Health. 2017. PMID: 28702175 Free PMC article.
-
Estimating the Economic Impact of Respiratory Syncytial Virus and Other Acute Respiratory Infections Among Infants Receiving Care at a Referral Hospital in Malawi.J Pediatric Infect Dis Soc. 2020 Dec 31;9(6):738-745. doi: 10.1093/jpids/piaa157. J Pediatric Infect Dis Soc. 2020. PMID: 33347578 Free PMC article.
-
Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis.J Infect Dis. 2020 Oct 7;222(Suppl 7):S680-S687. doi: 10.1093/infdis/jiz683. J Infect Dis. 2020. PMID: 32227101
-
Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.Lancet. 2024 Sep 21;404(10458):1143-1156. doi: 10.1016/S0140-6736(24)01716-1. Epub 2024 Sep 9. Lancet. 2024. PMID: 39265587 Review.
Cited by
-
Assessing the cost of illness of RSV and non-RSV acute respiratory infections in Nepali children.J Glob Health. 2025 Apr 11;15:04092. doi: 10.7189/jogh.15.04092. J Glob Health. 2025. PMID: 40208801 Free PMC article.
References
-
- Li Y, Johnson EK, Shi T, Campbell H, Chaves SS, Commaille-Chapus C, Dighero I, James SL, Mahe C, Ooi Y, et al. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study. Lancet Respir Med. 2021;9(2):175–85. 10.1016/S2213-2600(20)30322-2 - DOI - PubMed
-
- Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. 10.1016/S0140-6736(17)30938-8 - DOI - PMC - PubMed
-
- Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simoes EAF, Campbell H, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64. 10.1016/S0140-6736(22)00478-0 - DOI - PMC - PubMed
-
- Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55. 10.1016/S0140-6736(10)60206-1 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical